Last updated: July 31, 2026
Solu-Cortef is Pfizer’s injectable hydrocortisone sodium succinate product for systemic corticosteroid treatment when oral therapy is impractical. It is a mature, off-patent hospital medicine with demand tied to adrenal insufficiency, acute inflammatory disease, perioperative steroid replacement and critical-care use. Clinical development is focused on hydrocortisone as an active ingredient rather than on Solu-Cortef as a branded product. The principal commercial risk is generic substitution, while the main growth drivers are hospital utilization, emergency preparedness and demand for ready-to-use injectable presentations.
What is Solu-Cortef and how is it used?
Solu-Cortef contains hydrocortisone sodium succinate, a water-soluble corticosteroid prodrug that is converted to hydrocortisone after administration. Pfizer markets it as a sterile powder for solution and as the Act-O-Vial two-compartment presentation.
The product is administered intravenously or intramuscularly. The FDA label covers systemic corticosteroid use in conditions including:
- Primary or secondary adrenocortical insufficiency
- Acute adrenal crisis
- Severe allergic and inflammatory conditions
- Rheumatic disorders
- Gastrointestinal disease
- Respiratory disease
- Hematologic disorders
- Selected dermatologic and neurologic conditions
- Situations requiring rapid parenteral corticosteroid treatment
Solu-Cortef is not a biologic and does not require biosimilar approval. Its competitive set consists of generic hydrocortisone sodium succinate injections and other injectable corticosteroids, including methylprednisolone sodium succinate and dexamethasone sodium phosphate, where clinical substitution is appropriate.
What is the FDA regulatory status of Solu-Cortef?
Solu-Cortef is an FDA-approved prescription injectable corticosteroid. Pfizer’s labeling identifies hydrocortisone sodium succinate as the active ingredient and includes both conventional vials and Act-O-Vial configurations.[1]
| Regulatory attribute |
Solu-Cortef status |
| Active ingredient |
Hydrocortisone sodium succinate |
| Dosage form |
Powder for injection, including Act-O-Vial |
| Routes |
Intravenous and intramuscular |
| Regulatory class |
Small-molecule prescription drug |
| FDA pathway |
Legacy NDA product |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Therapeutic class |
Systemic corticosteroid |
| Primary institutional setting |
Hospitals, emergency departments and specialty care |
| Generic competition |
Established |
The product’s commercial position depends on hospital formularies, purchasing contracts, wholesaler availability and the operational value of the Act-O-Vial format. Its label supports broad systemic use, but individual hospital protocols determine when hydrocortisone is preferred over alternative corticosteroids.
What clinical trials are studying hydrocortisone?
Clinical-trial activity centers on hydrocortisone treatment strategies, dosing, timing and patient selection. Most studies do not identify Solu-Cortef as the investigational product because trials generally use the active ingredient or a local generic formulation.
Critical illness and septic shock
Hydrocortisone has been studied extensively in septic shock and vasopressor-dependent critical illness. Trial programs have evaluated whether intravenous hydrocortisone improves shock reversal, organ function, mortality, ventilator-free days or intensive-care outcomes.
The principal research questions are:
- Whether hydrocortisone should be administered continuously or intermittently.
- Whether fludrocortisone should be added to provide mineralocorticoid activity.
- Which patients have sufficient shock severity to justify corticosteroid exposure.
- Whether early treatment improves outcomes compared with rescue administration.
- How rapidly therapy should be tapered after hemodynamic stabilization.
The ADRENAL trial evaluated continuous hydrocortisone in mechanically ventilated patients with septic shock and did not show a significant 90-day mortality reduction, although hydrocortisone was associated with faster shock resolution and reduced duration of mechanical ventilation and intensive-care treatment in selected measures.[2] The APROCCHSS trial evaluated hydrocortisone plus fludrocortisone and reported lower 90-day mortality than placebo in its study population.[3]
These studies support continued clinical use of intravenous hydrocortisone in selected shock protocols, but they do not create new exclusivity for Solu-Cortef.
Adrenal crisis and adrenal insufficiency
Hydrocortisone remains the standard emergency replacement therapy for adrenal crisis. Current clinical research is directed toward:
- Earlier recognition of adrenal crisis
- Emergency self-injection systems
- Simplified dosing algorithms
- Pediatric emergency care
- Stress-dose treatment during infection or surgery
- Transition from parenteral to oral replacement
- Prevention of repeat emergency admissions
Solu-Cortef is commercially relevant in this setting because injectable hydrocortisone is widely used when patients cannot absorb oral therapy or present with hemodynamic instability. The greatest unmet need is often delivery convenience rather than a new molecule.
Perioperative corticosteroid replacement
Trials and observational studies continue to examine perioperative steroid coverage in patients receiving chronic glucocorticoid therapy or those with adrenal insufficiency. The market impact is incremental. Perioperative use is protocol-driven and generally involves low-cost generic hydrocortisone products.
Pediatric and neonatal use
Hydrocortisone research includes neonatal hypotension, congenital adrenal hyperplasia, adrenal insufficiency and stress dosing in children. Pediatric use can favor standardized emergency packaging, but it remains a relatively small portion of the overall injectable corticosteroid market.
When does Solu-Cortef lose exclusivity?
Solu-Cortef has no meaningful remaining market exclusivity based on its long commercial history and the availability of generic hydrocortisone sodium succinate injections. The key commercial protection is therefore brand recognition, manufacturing reliability, presentation design and hospital contracting rather than active patent exclusivity.
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Patent-based exclusivity |
No commercially meaningful remaining protection identified |
| Orphan exclusivity |
Not applicable to the broad product |
| Pediatric exclusivity |
No current commercial effect |
| Reference-product exclusivity |
Expired |
| Generic entry |
Established |
| Biosimilar protection |
Not applicable |
The FDA Orange Book should be checked for the current product-specific listing and any applicable patent entries because listing status can change through regulatory updates. For an old injectable product such as Solu-Cortef, the principal risk is usually abbreviated new drug application competition rather than Paragraph IV litigation.[4]
What patents protect Solu-Cortef?
No active composition-of-matter patent is expected to protect hydrocortisone sodium succinate as sold in Solu-Cortef. Hydrocortisone and its injectable salt have been used clinically for decades. Any historical patents covering the active ingredient, formulation or delivery presentation would have expired long ago.
Formulation patents
The Act-O-Vial presentation may be protected historically by mechanical, container, packaging or reconstitution concepts, but product-level commercial protection is limited where equivalent vial presentations are available. A competitor could avoid a specific container patent by using a conventional single-chamber vial or another reconstitution system.
Formulation-related barriers may still include:
- Sterility validation
- Powder stability
- Reconstitution performance
- Container-closure integrity
- Particulate control
- Manufacturing scale
- Extractables and leachables testing
- Hospital compatibility requirements
These are regulatory and manufacturing barriers rather than durable exclusivity rights.
Method-of-use patents
Solu-Cortef’s labeled uses are long-established medical applications. Method-of-use patents covering adrenal crisis, shock or general anti-inflammatory treatment would face substantial validity and enforcement challenges because of extensive prior clinical use. New patents could potentially cover a narrow dosing regimen, patient subgroup or combination treatment, but such patents would not ordinarily block generic hydrocortisone sodium succinate across the full product market.
Are there Paragraph IV challenges to Solu-Cortef?
Paragraph IV litigation is not the central competitive issue for Solu-Cortef. Generic hydrocortisone sodium succinate products are already commercially established, indicating that the market has moved beyond the initial patent-challenge phase.
A generic applicant may still certify against Orange Book patents if any are listed for a specific NDA, but that process would be product-specific. The greater risks to Pfizer are:
- Generic price competition
- Hospital conversion to lower-cost suppliers
- Group purchasing organization contracts
- Supply disruptions
- Competitor vial and syringe presentations
- State and institutional substitution policies
The absence of a current litigation-driven launch event reduces the probability of a single abrupt generic shock. Price erosion is more likely to occur through continuing procurement competition.
What is the Orange Book status of Solu-Cortef?
Solu-Cortef is associated with a legacy FDA-approved NDA and has generic hydrocortisone sodium succinate equivalents. The Orange Book remains the controlling source for current therapeutic-equivalence codes, patent listings and exclusivity information.[4]
For commercial diligence, the relevant checks are:
| Orange Book issue |
Business significance |
| Reference listed drug status |
Determines the generic approval reference |
| Therapeutic-equivalence codes |
Indicates substitutability of approved generic products |
| Patent listings |
Determines whether listed patents remain relevant |
| Exclusivity |
Identifies any regulatory delay to generic approval |
| Dosage-form matching |
Separates vial, Act-O-Vial and other presentations |
| Strength matching |
Affects hospital substitution and contracting |
The presence of generic equivalents means purchasers can often substitute on a strength and presentation basis, subject to institutional policy and product availability.
How strong is the Solu-Cortef patent estate?
The patent estate is weak as a source of exclusivity and moderate as an operational asset.
| Patent-estate dimension |
Assessment |
| Active ingredient protection |
Minimal or absent |
| Broad therapeutic-use protection |
Minimal |
| Formulation protection |
Limited |
| Device or packaging protection |
Potentially presentation-specific |
| Manufacturing know-how |
Moderate operational value |
| Brand recognition |
Stronger than patent protection |
| Regulatory moat |
Low to moderate |
| Supply-chain moat |
Potentially meaningful |
The product’s practical defensibility is based on regulatory familiarity, hospital purchasing relationships, quality systems, reliable supply and clinician recognition. These advantages can support a premium over the lowest-priced generic, but they do not prevent substitution.
Which companies compete with Solu-Cortef?
Competition comes from generic manufacturers and suppliers of alternative injectable corticosteroids.
Direct hydrocortisone sodium succinate competitors
The direct competitive field can include products marketed by companies such as:
- Hikma Pharmaceuticals
- Fresenius Kabi
- Sandoz
- Taro Pharmaceuticals
- Pfizer generic or legacy channels
- Other FDA-approved injectable generic manufacturers
The exact supplier set varies by strength, vial configuration, institutional contract and market availability.
Therapeutic alternatives
| Product |
Active ingredient |
Typical competitive role |
| Solu-Cortef |
Hydrocortisone sodium succinate |
Adrenal replacement and systemic corticosteroid therapy |
| Generic hydrocortisone sodium succinate |
Hydrocortisone sodium succinate |
Direct substitute |
| Solu-Medrol |
Methylprednisolone sodium succinate |
Higher-potency anti-inflammatory alternative |
| Generic methylprednisolone sodium succinate |
Methylprednisolone sodium succinate |
Broad hospital substitute |
| Dexamethasone injection |
Dexamethasone sodium phosphate |
Alternative where long duration and high potency are preferred |
Clinical interchangeability is not universal. Hydrocortisone has both glucocorticoid and mineralocorticoid activity, which can make it preferable in adrenal crisis and certain shock protocols.
What is the Solu-Cortef market outlook through 2030?
The injectable hydrocortisone market should remain mature and relatively stable through 2030. Growth is likely to come from healthcare utilization, emergency medicine and critical care rather than price expansion or patented innovation.
A reasonable scenario framework is:
| Scenario |
2024-2030 unit outlook |
Revenue outlook |
Main drivers |
| Downside |
Flat to low-single-digit decline |
Decline |
Generic price erosion and hospital substitution |
| Base case |
Low-single-digit unit growth |
Flat to low-single-digit growth |
Stable demand and modest volume expansion |
| Upside |
Mid-single-digit unit growth |
Low- to mid-single-digit growth |
Supply constraints, emergency-use growth and premium presentations |
These are market scenarios rather than a company-reported forecast. Solu-Cortef-specific revenue is not generally disclosed as a standalone line item in Pfizer’s public reporting. The product is part of a broader portfolio, making brand-level revenue estimation dependent on external prescription, hospital purchasing and channel data.[5]
Revenue exposure
Solu-Cortef is unlikely to be a major revenue driver for Pfizer relative to innovative medicines. Its strategic value is greater in portfolio breadth, hospital presence and supply continuity. A material revenue increase would require one or more of the following:
- Expansion of premium ready-to-use presentations
- Higher emergency and intensive-care utilization
- Reduced generic availability
- New institutional contracts
- Geographic expansion
- A differentiated delivery device
- Increased demand for emergency adrenal-crisis kits
Without new exclusivity, revenue growth is constrained by generic competition.
What generic launch scenarios exist for Solu-Cortef?
Generic competition is already established, so future scenarios concern additional suppliers, presentation substitution and supply-driven share shifts.
Scenario 1: Continued generic price erosion
Hospitals use competitive bidding to shift volume toward the lowest-cost approved supplier. Pfizer preserves a share of the market through brand familiarity and supply reliability, but average selling prices decline.
Scenario 2: Supply disruption
A shortage or manufacturing interruption at one or more generic suppliers can temporarily redirect demand to Solu-Cortef. This scenario can increase Pfizer’s unit volume but may not materially improve long-term pricing.
Scenario 3: Presentation-led retention
Pfizer retains higher-value accounts through Act-O-Vial convenience, established procurement specifications and reduced preparation burden. This protects share in emergency departments and operating rooms without creating legal exclusivity.
Scenario 4: New delivery competition
Ready-to-use syringes, autoinjectors or emergency kits could shift demand away from traditional vial formats. Such products would compete on speed, usability and error reduction rather than on hydrocortisone chemistry.
What litigation and settlement agreements affect Solu-Cortef?
No major current patent litigation or settlement event is central to the commercial outlook of Solu-Cortef. The product’s principal legal exposure is ordinary generic competition, manufacturing compliance, labeling, supply and product-liability risk.
The market does not appear to depend on a pending settlement date or a negotiated generic launch schedule. Any future dispute would more likely involve:
- Manufacturing or quality compliance
- Product contamination or recall
- Labeling
- Procurement contracts
- Supply allocation
- Patent claims directed to a new presentation
What manufacturing and intellectual-property barriers remain?
Manufacturing quality is more important than patent protection. Injectable corticosteroids must meet stringent requirements for sterility, potency, particulate limits and container integrity. A competitor must also demonstrate adequate stability after reconstitution and maintain reliable supply to hospitals.
The strongest practical barriers are:
- Sterile manufacturing capacity
- Validated aseptic processing
- Reliable active pharmaceutical ingredient supply
- Consistent fill-finish operations
- Regulatory inspection history
- Hospital vendor qualification
- Inventory and shortage management
- Ability to supply multiple strengths and vial configurations
These barriers can reduce the number of dependable suppliers even when many companies have legal permission to enter.
Key Takeaways
- Solu-Cortef is Pfizer’s injectable hydrocortisone sodium succinate product.
- It is a mature, off-patent medicine with established generic competition.
- Clinical research focuses on hydrocortisone use in septic shock, adrenal crisis, perioperative care and pediatric emergencies, not on branded Solu-Cortef development.
- No biosimilar pathway applies because Solu-Cortef is a small-molecule drug.
- Patent protection is not the principal commercial defense. Manufacturing reliability, hospital contracts and Act-O-Vial convenience are more relevant.
- Generic competition is established, making Paragraph IV litigation and settlement timing less important than ongoing price and supply competition.
- The market should remain stable through 2030, with low-single-digit unit growth in the base case and limited pricing power.
- Pfizer’s brand-level Solu-Cortef revenue is not separately reported in public financial disclosures.
- Supply disruption could temporarily improve branded demand, but long-term growth requires a differentiated presentation or delivery system.
Frequently Asked Questions
Is Solu-Cortef the same as hydrocortisone?
Solu-Cortef contains hydrocortisone sodium succinate, an injectable form of hydrocortisone designed for rapid systemic administration.
Is Solu-Cortef interchangeable with generic hydrocortisone?
Approved generic hydrocortisone sodium succinate products can compete directly with Solu-Cortef, but substitution depends on FDA therapeutic-equivalence status, product strength, presentation and institutional policy.
Does Solu-Cortef have biosimilar competition?
No. Biosimilars apply to biologic products. Solu-Cortef is a small-molecule corticosteroid and competes with generic drugs approved through the abbreviated new drug application pathway.
Does hydrocortisone have stronger patent protection than methylprednisolone?
Neither active ingredient has meaningful new-molecule patent protection in its established injectable form. Competition depends primarily on formulation, manufacturing, supply and hospital contracting.
Can a new hydrocortisone emergency injector obtain patent protection?
Yes. A new injector, formulation, dosing system or patient-specific delivery method could receive patents if it satisfies novelty, non-obviousness and other patentability requirements. Such protection would cover the differentiated delivery system, not necessarily hydrocortisone itself.
References
-
Pfizer Inc. (2023). Solu-Cortef (hydrocortisone sodium succinate) prescribing information. U.S. Food and Drug Administration.
-
The ADRENAL Trial Investigators. (2018). Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine, 378(9), 797-808. https://doi.org/10.1056/NEJMoa1705835
-
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J. P., Siami, S., et al. (2018). Hydrocortisone plus fludrocortisone for adults with septic shock. New England Journal of Medicine, 378(9), 809-818. https://doi.org/10.1056/NEJMoa1705716
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Pfizer Inc. (2024). Annual report 2023. https://www.pfizer.com/investors/financials/annual-reports###
